Medtronic to split diabetes business into separate entity, targets IPO
Medtronic has announced plans to separate out its diabetes business into a new standalone company. The separation will serve to…
Diabetes Care Devices
-
-
ŌURA rolls out glucose app linked with Dexcom’s CGM Stelo
ŌURA has signalled an entry into the consumer diabetes space, offering a new glucose feature for its ring that uses…
-
Endogenex reports results on ReCET system for type 2 diabetes management
Endogenex, a company focused on developing medical devices for type 2 diabetes management, has shared results from its REGENT-1 clinical…
-
Analysts say Dexcom’s FDA warning unlikely to impact 2025 revenue
Dexcom is still expected to hit 2025 revenue despite the diabetes device giant receiving a warning from the US Food…
-
Glucotrack hits trial success for direct blood measuring CGM
Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures glucose levels from a…
-
Beta Bionics raises $204m to kickstart medtech IPO season
Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its…
-
Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing
Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics…
-
How Dexcom and ŌURA are unifying two distinct market sectors
Technology has come a long way since the first blood glucose meter was developed by Anton H Clemens in 1965.…
-
JP Morgan 2025: Dexcom shares up 5% after 2025 outlook forecasts $4.6bn in revenue
Dexcom has shaken off the lower sales outlook that plagued its share price in 2024 as the diabetes device developer…
-
Dexcom implements GenAI into glucose biosensor devices
The applications of generative artificial intelligence (GenAI) have reached continuous glucose monitoring after DexCom launched rolled out the technology into…
